西陇科学股份有限公司 2019 年第三季度报告 2019 年 10 月 西陇科学股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人黄伟鹏、主管会计工作负责人杜修鸿及会计机构负责人(会计主 管人员)刘艳声明：保证季度报告中财务报表的真实、准确、完整。 2 西陇科学股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|---------------------------------------------------------------|--------------------------------------------|------ ...

西陇科学股份有限公司 2019 年半年度报告 2019 年 08 月 西陇科学股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人黄伟鹏、主管会计工作负责人杜修鸿及会计机构负责人(会计主 管人员)刘艳声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司在本报告第四节"经营情况讨论与分析"的"十、公司面临的风险和应对 措施"中描述了公司经营中可能存在的风险及应对的措施，敬请投资者关注相关 内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 西陇科学股份有限公司 2019 年半年度报告全文 目录 | --- | |--------------------------------------------------------------------------------------------------------------------------------- ...

西陇科学股份有限公司 2019 年第一季度报告全文 西陇科学股份有限公司 2019 年第一季度报告 2019 年 04 月 1 西陇科学股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人黄伟鹏、主管会计工作负责人蔡博及会计机构负责人(会计主管 人员)刘艳声明：保证季度报告中财务报表的真实、准确、完整。 2 西陇科学股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|--------------------------| | □ 是 √ 否 | 本报告期 | 上年同期 | 本报 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2018, representing a year-on-year growth of 15%[16] - The net profit attributable to shareholders was RMB 200 million, an increase of 10% compared to the previous year[16] - The company's operating revenue for 2018 was ¥3,444,849,645.30, representing a 4.22% increase from ¥3,305,218,530.48 in 2017[6] - The net profit attributable to shareholders for 2018 was ¥72,997,178.18, a decrease of 18.75% compared to ¥89,845,691.13 in 2017[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥43,450,923.27, down 41.10% from ¥73,764,448.34 in 2017[6] - The gross margin for the year was reported at 35%, slightly down from 37% in 2017 due to increased raw material costs[16] - The company reported a basic earnings per share of ¥0.12 for 2018, a decrease of 20.00% from ¥0.15 in 2017[6] - The company reported a net cash flow from operating activities for 2018 was -¥97,102,373.41, a decline of 404.56% from -¥19,245,071.29 in 2017[6] - The total assets at the end of 2018 were ¥3,509,208,885.60, an increase of 41.33% from ¥2,482,978,929.43 at the end of 2017[6] - The net assets attributable to shareholders at the end of 2018 were ¥1,760,122,160.18, up 3.72% from ¥1,696,970,242.70 at the end of 2017[6] Research and Development - The company plans to invest RMB 100 million in R&D for new product development in the upcoming year[16] - The company's R&D expenses increased by 38.04% to ¥81,745,372.66, up from ¥59,218,578.17 in the previous year[58] - The company’s R&D investment amounted to ¥81,803,757.13, which is 2.37% of operating revenue, up from 1.83% in the previous year[84] - The company has established a biochemistry diagnostic reagent R&D and production platform, enhancing its capabilities in the healthcare sector[52] - The company is focusing on R&D to support new business expansions and maintain product quality in a rapidly evolving market[114] Market Strategy and Expansion - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 30% increase in market share by 2020[16] - Future guidance indicates expected revenue growth of 20% for 2019, driven by new product launches and market expansion efforts[16] - The company is exploring potential mergers and acquisitions to enhance its product offerings and market presence[16] - The electronic chemicals sector is expected to grow rapidly, driven by advancements in downstream industries such as semiconductors and solar energy[110] Product Development - A new product line in electronic chemicals is expected to launch in Q3 2019, projected to contribute an additional RMB 300 million in revenue[16] - The company continues to focus on the production, research and development, and sales of chemical reagents, while also expanding into in vitro diagnostic reagents and gene sequencing services[39] - The company has doubled its product varieties in electronic chemicals compared to the same period last year, responding to market demand[44] Financial Management - The company has no plans to distribute cash dividends or issue bonus shares for the year 2018[7] - The company has not distributed cash dividends or issued new shares in the 2018 profit distribution plan, pending shareholder approval[119] - The company has a three-year shareholder return plan (2017-2019) that outlines specific conditions and ratios for profit distribution[119] - The company did not distribute any cash dividends in 2017 and 2018, indicating a shift in strategy towards reinvestment[123] - The retained earnings will be used for daily operations and investments in high-end medical services, genetic testing, and in vitro diagnostics[123] Operational Efficiency - The company has strengthened its internal management to enhance efficiency and reduce costs amid competitive pressures[111] - The company is actively adjusting its product structure and optimizing production processes to comply with stricter environmental regulations[112] - The company has invested in safety measures to mitigate risks associated with hazardous materials in production[111] Acquisitions and Partnerships - The company acquired 73.78% of Shandong Aikwei Biotechnology Co., Ltd. for 431,363,508.29 in cash on May 31, 2018[70] - The company has formed strategic partnerships with major clients, including Intel and other semiconductor companies, to expand its market presence[50] - The company has integrated its medical sector through acquisitions, covering biological reagents, in vitro diagnostics, and gene sequencing[56] Corporate Governance and Compliance - The company has committed to avoiding competition with its actual controllers and has plans for the reconstruction of properties at risk of demolition[129] - The company has ensured compliance with regulations regarding non-public offerings and will not provide financial assistance to investors participating in the issuance[135] - The company has confirmed that there are no structured arrangements or tiered returns in its asset management products[133] - The company has stated that it will not engage in any related transactions or competition with its partners post-issuance[135] Social Responsibility and Safety - The company emphasizes corporate social responsibility and maintains effective communication with investors[194][196] - The company has established a comprehensive safety inspection and rectification system, integrating various types of inspections[197] - There were no major safety production accidents reported during the period, and the company has not been penalized for violating safety production laws[197] Challenges and Risks - The company has implemented risk control measures since 2012, ensuring that no overdue payments occurred before 2018, but faced difficulties in customer repayments in 2018 due to adverse market conditions[146] - The company plans to strengthen customer management and assessment, and gradually reduce the scale of the agency business to mitigate risks[147]

西陇科学股份有限公司 2018 年第三季度报告正文 证券代码：002584 证券简称：西陇科学 公告编号：2018-100 西陇科学股份有限公司 2018 年第三季度报告正文 1 西陇科学股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人黄伟鹏、主管会计工作负责人蔡博及会计机构负责人(会计主管 人员)刘艳声明：保证季度报告中财务报表的真实、准确、完整。 2 西陇科学股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 3,097,861,994.41 | 2,482,978,929.43 | | 24.76% | | 归属于上市公司股东的净 ...

西陇科学股份有限公司 2018 年半年度报告全文 西陇科学股份有限公司 2018 年半年度报告 2018 年 08 月 1 西陇科学股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人黄伟鹏、主管会计工作负责人蔡博及会计机构负责人(会计主管 人员)刘艳声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及未来计划等前瞻性陈述或计划，该陈述或计划不构成对投资者 的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理 解计划、预测与承诺之间的差异。 本公司敬请投资者认真阅读报告全文，并特别注意以下风险因素：安全风 险、环保风险，研发风险、管理风险等，详见经营情况讨论与分析章节公司面 临的风险和应对措施部分。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介和 ...

西陇科学股份有限公司 2018 年第一季度报告正文 证券代码：002584 证券简称：西陇科学 公告编号：2018-037 西陇科学股份有限公司 2018 年第一季度报告正文 1 西陇科学股份有限公司 2018 年第一季度报告正文 西陇科学股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 768,827,530.12 | 723,239,352.24 | 6.30% | | 归属于上市公司股东的净利润（元） | 9,441,163.23 | 6,708,366.31 | 40.74% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 5,022,239.26 | 5,085,079.15 | -1.24% | | 经营活动产生的现金流量净额（元） | -130,799,424.29 | -93,752,316.74 | -39.52% | | 基本每股收益 ...

西陇科学股份有限公司 2017 年年度报告全文 西陇科学股份有限公司 2017 年年度报告 2018 年 03 月 1 西陇科学股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人黄伟鹏、主管会计工作负责人韦映吟及会计机构负责人(会计主 管人员)刘艳声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及未来计划等前瞻性陈述或计划，该陈述或计划不构成对投资者 的实质承诺，投资者及相关认识均应当对此保持足够的风险认识，并且应当理 解计划、预测与承诺之间的差异。 本公司请投资者认真阅读年度报告全文，并特别注意以下风险因素：安全 风险、环保风险，研发风险、管理风险等，详见经营情况讨论与分析章节未来 发展展望部分。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | | 第二节 | 公司简介和主要财务指标 | | 5 | | --- | --- | --- ...

西陇科学股份有限公司 2017 年第三季度报告正文 证券代码：002584 证券简称：西陇科学 公告编号：2017-068 西陇科学股份有限公司 2017 年第三季度报告正文 1 西陇科学股份有限公司 2017 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人黄伟鹏、主管会计工作负责人韦映吟及会计机构负责人(会计主 管人员)刘艳声明：保证季度报告中财务报表的真实、准确、完整。 2 西陇科学股份有限公司 2017 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,398,291,975.69 | 2,372,548,499.96 | | 1.09% | | 归属于上市公司股东的净 ...

Financial Performance - The company's operating revenue for the first half of 2017 was ¥1,586,892,933.10, representing a 45.11% increase compared to ¥1,093,587,743.75 in the same period last year[15]. - The net profit attributable to shareholders of the listed company decreased by 36.19% to ¥35,244,630.85 from ¥55,234,988.29 year-on-year[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 57.86% to ¥20,011,051.13 compared to ¥47,492,480.61 in the previous year[15]. - Basic earnings per share decreased by 33.33% to ¥0.06 from ¥0.09 year-on-year[15]. - The total revenue for the first half of 2017 was ¥1,586,892,933.10, representing a 45.11% increase compared to ¥1,093,587,743.75 in the same period last year[37]. - Revenue from the chemical industry reached ¥1,570,866,518.19, accounting for 98.99% of total revenue, with a year-on-year growth of 52.43%[39]. - The revenue from the medical industry (instruments and diagnostic reagents) significantly decreased by 74.96%, totaling ¥15,787,639.06, due to the transfer of 51% equity in a subsidiary[39]. - The revenue from chemical raw materials surged by 123.60% to ¥870,416,760.08, driven by the launch of the e-commerce platform "Youliao.com"[39]. - The gross profit margin for the chemical industry was 12.22%, with a decrease of 6.90% compared to the previous year[38]. - The company reported a total profit of CNY 34,343,704.31, compared to CNY 71,058,697.52 in the previous year, indicating a decline of around 52%[129]. - The company reported a significant decrease in accounts receivable, totaling ¥344,229,291.66, down 2.24% from the previous year[41]. Cash Flow and Financial Position - The net cash flow from operating activities improved by 30.92%, reaching -¥47,879,817.32 compared to -¥69,315,429.34 in the previous year[15]. - Cash and cash equivalents at the end of the reporting period amounted to ¥463,779,248.92, representing 19.81% of total assets[41]. - Short-term borrowings increased to ¥170,029,896.95, up 3.12% from the previous year[41]. - The company reported a cash inflow of 522,530,098.61 CNY from sales, which is an increase from 298,755,851.83 CNY in the previous period, indicating improved sales performance[139]. - The total cash inflow from operating activities was 530,201,097.30 CNY, up from 335,443,160.29 CNY, reflecting a positive trend in operational cash generation[139]. - The company received 347,247,233.78 CNY from borrowings, a significant increase from 138,919,077.17 CNY in the previous period, indicating increased reliance on debt financing[139]. - The total amount of entrusted financial management funds reached 18,585 million, with an interest income of 30.43 million[93]. Investments and R&D - Research and development expenses rose by 5.58% to ¥20,851,680.61 from ¥19,749,275.73, indicating continued investment in innovation[34]. - The company is actively developing biological reagents, focusing on the research and market promotion of in vitro diagnostic reagents[32]. - The company has 23 valid authorized patents, reflecting its commitment to enhancing intellectual property utilization[26]. - The company’s gene sequencing business is progressing steadily, with a strategic partnership established for genetic testing services[31]. Risks and Challenges - The company faces risks including safety production, environmental protection, technology research and development, and management[4]. - The company faced challenges in the chemical raw material market, leading to uncertain profitability, while gene sequencing services are still in the market cultivation phase, resulting in high initial expenditures[56]. - Environmental risks have been heightened due to stricter regulations, prompting the company to adjust its product structure and optimize production processes for energy conservation and emission reduction[59]. Corporate Governance and Shareholder Matters - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has not declared any cash dividends for the first half of 2017, with plans to maintain a cash dividend policy of at least 10% of distributable profits in the future[67]. - The company plans to increase cash dividend ratios if net profits continue to grow steadily over the next three years, aiming for a cumulative distribution of at least 30% of the average distributable profits during that period[67]. - The company has committed to a minimum profit distribution ratio of 20% in its profit allocation plan[69]. - The company has no major contracts or leasing arrangements in place during the reporting period[83][84][85]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[106]. Legal and Compliance - There were no significant litigation or arbitration matters during the reporting period[72]. - The company faced a lawsuit regarding a share transfer dispute, with a total amount involved of 1,295,700.00 CNY, which has been executed[73]. - The company reported no major penalties or rectification situations during the reporting period[75]. - The company has no violations regarding external guarantees during the reporting period[89]. Accounting and Financial Reporting - The semi-annual financial report for the company has not been audited[70]. - The financial report for the first half of 2017 has not been audited[117]. - The company’s financial statements are prepared based on the assumption of going concern, with no significant doubts about its ability to continue operations[167]. - The company’s accounting policies are aligned with the enterprise accounting standards, ensuring accurate financial reporting[169].